MedPath

Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer

Phase 1
Completed
Conditions
Prostate Cancer
Interventions
Registration Number
NCT01324583
Lead Sponsor
Sanofi
Brief Summary

Primary Objective:

* To assess the tolerability at global doses

Secondary Objectives:

* Safety

* Pharmacokinetics

* Efficacy

Detailed Description

The duration of screening within 28 days, treatment 3 weeks/cycle and follow-up 30 days after the last cabazitaxel administration.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
48
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Arm 1Cabazitaxel (XRP6258)Patients will receive cabazitaxel as the dose of corresponded level 1-hour intravenous infusion every 3 weeks plus prednisolone 10 mg orally given daily: Dose Level Cabazitaxel Dose Level -1: 15 mg/m², Level 1: 20 mg/m², Level 2: 25 mg/m²
Arm 1prednisolonePatients will receive cabazitaxel as the dose of corresponded level 1-hour intravenous infusion every 3 weeks plus prednisolone 10 mg orally given daily: Dose Level Cabazitaxel Dose Level -1: 15 mg/m², Level 1: 20 mg/m², Level 2: 25 mg/m²
Primary Outcome Measures
NameTimeMethod
Identification of maximum tolerated doseup to 18 months
Secondary Outcome Measures
NameTimeMethod
Pharmakokinetic parameters of Cabazitaxelup to 18 months
number of participants with treatment emergent adverse eventsup to 18 months
Prostate Specific Antigen (PSA) Responseup to 18 months

Trial Locations

Locations (21)

Investigational Site Number 392008

🇯🇵

Maebashi-Shi, Japan

Investigational Site Number 392015

🇯🇵

Nagoya-Shi, Japan

Investigational Site Number 392003

🇯🇵

Sunto-Gun, Japan

Investigational Site Number 392011

🇯🇵

Bunkyo-Ku, Japan

Investigational Site Number 392021

🇯🇵

Fukuoka-Shi, Japan

Investigational Site Number 392014

🇯🇵

Hamamatsu-Shi, Japan

Investigational Site Number 392009

🇯🇵

Itabashi-Ku, Japan

Investigational Site Number 392001

🇯🇵

Kashiwa-Shi, Japan

Investigational Site Number 392020

🇯🇵

Kita-Gun, Japan

Investigational Site Number 392002

🇯🇵

Koto-Ku, Japan

Investigational Site Number 392016

🇯🇵

Kyoto-Shi, Japan

Investigational Site Number 392017

🇯🇵

Kyoto-Shi, Japan

Investigational Site Number 392012

🇯🇵

Minato-Ku, Japan

Investigational Site Number 392019

🇯🇵

Osaka Sayama-Shi, Japan

Investigational Site Number 392004

🇯🇵

Sapporo-Shi, Japan

Investigational Site Number 392005

🇯🇵

Sendai-Shi, Japan

Investigational Site Number 392010

🇯🇵

Shinjuku-Ku, Japan

Investigational Site Number 392018

🇯🇵

Suita-Shi, Japan

Investigational Site Number 392007

🇯🇵

Tsukuba-Shi, Japan

Investigational Site Number 392013

🇯🇵

Yokohama-Shi, Japan

Investigational Site Number 392006

🇯🇵

Yamagata-Shi, Japan

© Copyright 2025. All Rights Reserved by MedPath